[1]
Vargas DL, Tyor WR. Update on disease-modifying therapies for multiple sclerosis. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 2017 Jun:65(5):883-891. doi: 10.1136/jim-2016-000339. Epub 2017 Jan 27
[PubMed PMID: 28130412]
[2]
Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. The New England journal of medicine. 2005 Jul 28:353(4):369-74
[PubMed PMID: 15947079]
[3]
Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. The Lancet. Neurology. 2009 Mar:8(3):254-60. doi: 10.1016/S1474-4422(09)70021-3. Epub 2009 Feb 7
[PubMed PMID: 19201654]
Level 2 (mid-level) evidence
[4]
Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. Journal of the neurological sciences. 2010 May 15:292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16
[PubMed PMID: 20236661]
[5]
Lu ZY, Chen WC, Li YH, Li L, Zhang H, Pang Y, Xiao ZF, Xiao HW, Xiao Y. TNF-α enhances vascular cell adhesion molecule-1 expression in human bone marrow mesenchymal stem cells via the NF-κB, ERK and JNK signaling pathways. Molecular medicine reports. 2016 Jul:14(1):643-8. doi: 10.3892/mmr.2016.5314. Epub 2016 May 19
[PubMed PMID: 27221006]
[6]
Kanwar JR, Kanwar RK, Wang D, Krissansen GW. Prevention of a chronic progressive form of experimental autoimmune encephalomyelitis by an antibody against mucosal addressin cell adhesion molecule-1, given early in the course of disease progression. Immunology and cell biology. 2000 Dec:78(6):641-5
[PubMed PMID: 11114975]
[7]
Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology. 2005 Apr 26:64(8):1336-42
[PubMed PMID: 15851719]
[8]
Gerardi C, Bertele' V, Rossi S, Garattini S, Banzi R. Preapproval and postapproval evidence on drugs for multiple sclerosis. Neurology. 2018 May 22:90(21):964-973. doi: 10.1212/WNL.0000000000005561. Epub 2018 Apr 25
[PubMed PMID: 29695598]
[9]
Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebic S, Sitcov C, Sommers R, Stachowiak J, Getchius TSD, Merillat SA, Pringsheim T. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018 Apr 24:90(17):777-788. doi: 10.1212/WNL.0000000000005347. Epub
[PubMed PMID: 29686116]
Level 1 (high-level) evidence
[11]
Stüve O, Hemmer B. The genetics of natalizumab hypersensitivity: One learns to itch where one can scratch. Neurology(R) neuroimmunology & neuroinflammation. 2014 Dec:1(4):e52. doi: 10.1212/NXI.0000000000000052. Epub 2014 Dec 11
[PubMed PMID: 25520959]
[12]
Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. The Lancet. Neurology. 2017 Nov:16(11):925-933. doi: 10.1016/S1474-4422(17)30282-X. Epub 2017 Sep 29
[PubMed PMID: 28969984]
Level 2 (mid-level) evidence
[13]
Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. The New England journal of medicine. 2012 May 17:366(20):1870-80. doi: 10.1056/NEJMoa1107829. Epub
[PubMed PMID: 22591293]
[14]
Gasim M, Bernstein CN, Graff LA, Patten SB, El-Gabalawy R, Sareen J, Bolton JM, Marriott JJ, Fisk JD, Marrie RA, CIHR team “Defining the burden and managing the effects of psychiatric comorbidity in chronic inflammatory disease”. Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review. Multiple sclerosis and related disorders. 2018 Nov:26():124-156. doi: 10.1016/j.msard.2018.09.008. Epub 2018 Sep 12
[PubMed PMID: 30248593]
Level 1 (high-level) evidence
[15]
Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, Jäger HR, Clifford DB. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. The New England journal of medicine. 2006 Mar 2:354(9):924-33
[PubMed PMID: 16510746]